Abstract Details
|
PRESENTER |
No disclosure on file |
| No disclosure on file | |
| Maria E. Gonzalez Toledo, MD | No disclosure on file |
| No disclosure on file | |
| No disclosure on file | |
| Agustina Tamargo | No disclosure on file |
| No disclosure on file | |
| No disclosure on file | |
| No disclosure on file | |
| Vern C. Juel, MD, FAAN (Duke University Medical Center) | Dr. Juel has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Juel has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immunovant. The institution of Dr. Juel has received research support from argenx. The institution of Dr. Juel has received research support from Alexion. The institution of Dr. Juel has received research support from Janssen. The institution of Dr. Juel has received research support from NIH Rare Diseases Network. |
| Vern C. Juel, MD, FAAN (Duke University Medical Center) | Dr. Juel has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Juel has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immunovant. The institution of Dr. Juel has received research support from argenx. The institution of Dr. Juel has received research support from Alexion. The institution of Dr. Juel has received research support from Janssen. The institution of Dr. Juel has received research support from NIH Rare Diseases Network. |